Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - amoxicillin trihydrate,clarithromycin,esomeprazole magnesium -

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - amoxicillin trihydrate,clarithromycin,esomeprazole magnesium -

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

jubilant pharma australia pty ltd - esomeprazole magnesium trihydrate, quantity: 44.528 mg - tablet, enteric coated - excipient ingredients: pregelatinised maize starch; povidone; macrogol 400; purified talc; light magnesium oxide; polysorbate 80; hypromellose phthalate; silicon dioxide; hyprolose; methacrylic acid - ethyl acrylate copolymer (1:1); microcrystalline cellulose; macrogol 6000; glyceryl monostearate; crospovidone; iron oxide red; titanium dioxide; hypromellose; maize starch; sucrose - esomeprazole jgl is indicated for: gastro-oesophageal reflux disease (gord). ? treatment of erosive reflux oesophagitis ? long-term management of patients with healed oesophagitis to prevent relapse ? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy. ? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti- inflammatory drug nsaid (non-selective and cox-2 selective) therapy. ? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy ? prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv (available in other brands) solution by intravenous infusion. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for: ? healing of duodenal ulcer associated with helicobacter pylori ? eradication of helicobacter pylori in patients with active or healed peptic ulcer

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

jubilant pharma australia pty ltd - esomeprazole magnesium trihydrate, quantity: 44.528 mg - tablet, enteric coated - excipient ingredients: iron oxide red; povidone; microcrystalline cellulose; silicon dioxide; methacrylic acid - ethyl acrylate copolymer (1:1); glyceryl monostearate; macrogol 6000; macrogol 400; crospovidone; polysorbate 80; hypromellose phthalate; pregelatinised maize starch; purified talc; light magnesium oxide; hyprolose; titanium dioxide; hypromellose; maize starch; sucrose - esomeprazole sps is indicated for: gastro-oesophageal reflux disease (gord). ? treatment of erosive reflux oesophagitis ? long-term management of patients with healed oesophagitis to prevent relapse ? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy. ? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti- inflammatory drug nsaid (non-selective and cox-2 selective) therapy. ? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy ? prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv (available in other brands) solution by intravenous infusion. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for: ? healing of duodenal ulcer associated with helicobacter pylori ? eradication of helicobacter pylori in patients with active or healed peptic ulcer

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

jubilant pharma australia pty ltd - esomeprazole magnesium trihydrate, quantity: 44.528 mg - tablet, enteric coated - excipient ingredients: polysorbate 80; macrogol 400; silicon dioxide; crospovidone; hypromellose phthalate; glyceryl monostearate; purified talc; iron oxide red; pregelatinised maize starch; microcrystalline cellulose; povidone; macrogol 6000; hyprolose; methacrylic acid - ethyl acrylate copolymer (1:1); light magnesium oxide; titanium dioxide; hypromellose; maize starch; sucrose - esomeprazole sps is indicated for: gastro-oesophageal reflux disease (gord). ? treatment of erosive reflux oesophagitis ? long-term management of patients with healed oesophagitis to prevent relapse ? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy. ? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti- inflammatory drug nsaid (non-selective and cox-2 selective) therapy. ? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy ? prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv (available in other brands) solution by intravenous infusion. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for: ? healing of duodenal ulcer associated with helicobacter pylori ? eradication of helicobacter pylori in patients with active or healed peptic ulcer

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

jubilant pharma australia pty ltd - esomeprazole magnesium trihydrate, quantity: 44.528 mg - tablet, enteric coated - excipient ingredients: pregelatinised maize starch; polysorbate 80; iron oxide red; microcrystalline cellulose; hyprolose; macrogol 6000; povidone; macrogol 400; hypromellose phthalate; crospovidone; purified talc; light magnesium oxide; silicon dioxide; methacrylic acid - ethyl acrylate copolymer (1:1); glyceryl monostearate; titanium dioxide; hypromellose; maize starch; sucrose - esomeprazole jgl is indicated for: gastro-oesophageal reflux disease (gord). ? treatment of erosive reflux oesophagitis ? long-term management of patients with healed oesophagitis to prevent relapse ? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy. ? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti- inflammatory drug nsaid (non-selective and cox-2 selective) therapy. ? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy ? prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv (available in other brands) solution by intravenous infusion. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for: ? healing of duodenal ulcer associated with helicobacter pylori ? eradication of helicobacter pylori in patients with active or healed peptic ulcer

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

jubilant pharma australia pty ltd - esomeprazole magnesium trihydrate, quantity: 22.264 mg - tablet, enteric coated - excipient ingredients: purified talc; macrogol 400; hypromellose phthalate; macrogol 6000; iron oxide red; pregelatinised maize starch; silicon dioxide; crospovidone; glyceryl monostearate; light magnesium oxide; polysorbate 80; povidone; microcrystalline cellulose; hyprolose; methacrylic acid - ethyl acrylate copolymer (1:1); titanium dioxide; hypromellose; iron oxide yellow; maize starch; sucrose - esomeprazole sps is indicated for: gastro-oesophageal reflux disease (gord). ? treatment of erosive reflux oesophagitis ? long-term management of patients with healed oesophagitis to prevent relapse ? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy. ? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti- inflammatory drug nsaid (non-selective and cox-2 selective) therapy. ? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy ? prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv (available in other brands) solution by intravenous infusion. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for: ? healing of duodenal ulcer associated with helicobacter pylori ? eradication of helicobacter pylori in patients with active or healed peptic ulcer

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

jubilant pharma australia pty ltd - esomeprazole magnesium trihydrate, quantity: 22.264 mg - tablet, enteric coated - excipient ingredients: iron oxide red; purified talc; microcrystalline cellulose; methacrylic acid - ethyl acrylate copolymer (1:1); macrogol 400; silicon dioxide; pregelatinised maize starch; hypromellose phthalate; glyceryl monostearate; crospovidone; polysorbate 80; povidone; light magnesium oxide; macrogol 6000; hyprolose; titanium dioxide; hypromellose; iron oxide yellow; maize starch; sucrose - esomeprazole jgl is indicated for: gastro-oesophageal reflux disease (gord). ? treatment of erosive reflux oesophagitis ? long-term management of patients with healed oesophagitis to prevent relapse ? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy. ? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti- inflammatory drug nsaid (non-selective and cox-2 selective) therapy. ? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy ? prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv (available in other brands) solution by intravenous infusion. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for: ? healing of duodenal ulcer associated with helicobacter pylori ? eradication of helicobacter pylori in patients with active or healed peptic ulcer

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

jubilant pharma australia pty ltd - esomeprazole magnesium trihydrate, quantity: 22.264 mg - tablet, enteric coated - excipient ingredients: methacrylic acid - ethyl acrylate copolymer (1:1); povidone; glyceryl monostearate; light magnesium oxide; silicon dioxide; microcrystalline cellulose; crospovidone; macrogol 400; macrogol 6000; purified talc; polysorbate 80; iron oxide red; hypromellose phthalate; pregelatinised maize starch; hyprolose; titanium dioxide; hypromellose; iron oxide yellow; maize starch; sucrose - esomeprazole sps is indicated for: gastro-oesophageal reflux disease (gord). ? treatment of erosive reflux oesophagitis ? long-term management of patients with healed oesophagitis to prevent relapse ? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy. ? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti- inflammatory drug nsaid (non-selective and cox-2 selective) therapy. ? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy ? prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv (available in other brands) solution by intravenous infusion. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for: ? healing of duodenal ulcer associated with helicobacter pylori ? eradication of helicobacter pylori in patients with active or healed peptic ulcer

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

jubilant pharma australia pty ltd - esomeprazole magnesium trihydrate, quantity: 22.264 mg - tablet, enteric coated - excipient ingredients: hypromellose phthalate; microcrystalline cellulose; hyprolose; purified talc; crospovidone; macrogol 6000; glyceryl monostearate; methacrylic acid - ethyl acrylate copolymer (1:1); light magnesium oxide; pregelatinised maize starch; povidone; iron oxide red; macrogol 400; silicon dioxide; polysorbate 80; titanium dioxide; hypromellose; iron oxide yellow; maize starch; sucrose - esomeprazole jgl is indicated for: gastro-oesophageal reflux disease (gord). ? treatment of erosive reflux oesophagitis ? long-term management of patients with healed oesophagitis to prevent relapse ? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy. ? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti- inflammatory drug nsaid (non-selective and cox-2 selective) therapy. ? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy ? prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv (available in other brands) solution by intravenous infusion. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for: ? healing of duodenal ulcer associated with helicobacter pylori ? eradication of helicobacter pylori in patients with active or healed peptic ulcer